Psychedelic Therapy Access in Europe: Comparison
Compare ketamine and esketamine licensing, reimbursement, and patient access pathways across selected European markets.
Published on 4/17/2026
Europe access comparison
This resource provides a side-by-side view of ketamine and esketamine access pathways across selected European markets, with a focus on licensing status, reimbursement, and practical availability.
How to use this comparison
- Use this table as a market-scoping reference when prioritising evidence, payer, and service-readiness planning.
- Re-validate entries before publication decisions, as reimbursement conditions can change quickly across jurisdictions.